Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Alx Oncology Holdings Inc (ALXO)
Price$2.01Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $1.2M | $4.8M | $2.1M |
| Research & development | $77.0M | $116.4M | $141.8M | $98.4M | $60.2M | $29.0M | $16.3M | $11.3M |
| Operating expenses | $104.0M | $142.5M | $170.3M | $127.4M | $83.6M | $44.8M | $24.0M | $15.8M |
| Operating income | −$104.0M | −$142.5M | −$170.3M | −$127.4M | −$83.6M | −$43.7M | −$19.2M | −$13.7M |
| Operating margin | — | — | — | — | — | −3,693.99% | −399.98% | −662.02% |
| EBITDA | −$103.3M | −$141.6M | −$169.4M | −$127.1M | −$83.5M | −$43.5M | −$18.8M | −$13.3M |
| EBITDA margin | — | — | — | — | — | −3,676.90% | −391.03% | −641.17% |
| Net income | −$101.7M | −$134.8M | −$160.8M | −$123.5M | −$83.5M | −$45.7M | −$19.2M | −$13.7M |
| Net profit margin | — | — | — | — | — | −3,869.71% | −401.23% | −664.30% |
| Basic EPSper basic share | -$1.90 | -$2.58 | -$3.74 | -$3.03 | -$2.07 | -$2.76 | -$7.56 | -$6.33 |
| Diluted EPSper diluted share | -$1.90 | -$2.58 | -$3.74 | -$3.03 | -$2.07 | -$2.76 | -$7.56 | -$6.33 |
Owners
Reported shareholders
9.41%of listed shares
RA CAPITAL MANAGEMENT, L.P.13.01M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
RA CAPITAL MANAGEMENT, L.P. | 9.41%13.01M shares |
venBio Partners LLC | 9.32%12.88M shares |
BlackRock, Inc. | 5.35%7.4M shares |
Redmile Group, LLC | 5.35%7.39M shares |
Blackstone Inc. | 4.77%6.59M shares |
Driehaus Capital Management LLC | 4.36%6.03M shares |
SILVERARC CAPITAL MANAGEMENT, LLC | 4.16%5.74M shares |
TCG Crossover Management, LLC | 4.09%5.66M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.60%4.97M shares |
Vivo Capital, LLC | 2.30%3.18M shares |
MARSHALL WACE, LLP | 2.22%3.07M shares |
5AM Venture Management, LLC | 2.21%3.06M shares |
Almitas Capital LLC | 2.13%2.94M shares |
ORBIMED ADVISORS LLC | 2.07%2.87M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.02%2.79M shares |
TWO SIGMA INVESTMENTS, LP | 1.58%2.18M shares |
MILLENNIUM MANAGEMENT LLC | 1.12%1.54M shares |
Nantahala Capital Management, LLC | 1.09%1.5M shares |
STATE STREET CORP | 1.08%1.5M shares |
ACADIAN ASSET MANAGEMENT LLC | 0.95%1.31M shares |
Percentages use 138.22M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 19, 2026Form 4 | Lettmann JasonCHIEF EXECUTIVE OFFICER | SellCommon Stock | 12.3K | $2.17 | $26.7K | 293.6K |
| Mar 19, 2026Form 4 | Pinto ShellySVP, FINANCE AND CAO | SellCommon Stock | 903 | $2.17 | $2.0K | 86.8K |
| Feb 18, 2026Form 4 | Pinto ShellySVP, FINANCE AND CAO | SellCommon Stock | 565 | $2.27 | $1.3K | 87.7K |
| Feb 2, 2026Form 4 | GOODMAN COREY SDirector,TenPercentOwner | BuyCommon Stock · indirect | 3.18M | $1.57 | $5.00M | 8.45M |
| Jan 6, 2026Form 4 | Pinto ShellySVP, FINANCE AND CAO | SellCommon Stock | 3.9K | $1.11 | $4.4K | 88.3K |